LLY spotlight — 2026-10-01
Eli Lilly & Co (LLY) is down 2.33% from the prior close, marking a notable divergence in its performance over different time horizons: it’s up 59.27% over the past year but has seen a decline of -2.91% over the last three months. This…
Key figures
Data as of Oct 1, 2026- LLY last close
- $1,157.08
- LLY change vs prior close
- -2.33%
- LLY trailing P/E
- 39.51
- LLY market cap
- $1.06T
Eli Lilly & Co (LLY) is down 2.33% from the prior close¹, marking a notable divergence in its performance over different time horizons: it’s up 59.27% over the past year but has seen a decline of -2.91% over the last three months²˒³. This mixed picture is further complicated by recent news sentiment, which skews overwhelmingly positive with 10 positive articles and no negative ones⁴.
LLY closed at $1157.08 on Wednesday⁵, within the higher range of its 52-week trading band (76.1%) but well below its high point of $1292.65 set over the past year⁶˒⁷. The company’s P/E ratio stands at 39.51, and it has a market cap of approximately $1.06T⁸˒⁹.
Recent coverage highlights promising developments in Lilly's new weight loss drug, with reports indicating significant weight loss among patients. Despite this positive news, the stock’s three-month performance suggests caution from investors or other external factors at play.
Eli Lilly & Co. (LLY): price and news
Full chart and figuresDaily closes up to Sep 30, 2026, the last session before this was written.
News
- Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?The Motley FoolSep 30Positive
Currently the market leader in weight loss drugs with Zepbound. The company has an exceptionally strong pipeline including retatrutide, which posted outstanding Phase 3 results. Deep pipeline and market position provide competitive advantages.
- Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?The Motley FoolSep 29Positive
LLY is recommended as the superior choice due to explosive 45% revenue growth, market-leading GLP-1 drugs (Zepbound, Mounjaro), strong net margins (32%), anticipated blockbuster pipeline (Retatrutide, lipoprotein(a) therapeutic), forecast for 30% revenue growth in 2026, and direct-to-consumer expansion. Despite higher valuation multiples, growth prospects justify the premium.
- Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.The Motley FoolSep 29Positive
Market leader in weight-loss drugs with strong financial results, sophisticated multi-pronged maintenance strategies (Foundayo, dose reduction), promising next-gen medicine (retatrutide), and diversified pipeline. Stock stability despite competitor's positive news demonstrates investor confidence.
- Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?The Motley FoolSep 28Neutral
Acknowledged as a market leader in GLP-1 space with strong historical returns (400% in 5 years), but characterized as having limited future upside potential due to high valuation and large market cap, making it less attractive for growth investors.
- Here's Where Wall Street Analysts See Eli Lilly's Share Price GoingThe Motley FoolSep 26Positive
Strong market position with world's best-selling drug (tirzepatide), expanding GLP-1 market opportunity ($190B by 2045), robust patent protection through late 2030s, and 25 of 30 analysts recommending buy with average 11% upside target. Current valuation at 40x earnings is high but justified by growth prospects.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Educational tool. Not investment advice. This article was produced with automated assistance. Every figure in it was checked against the underlying data before it was published; the interpretation was not.